Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study

Authors: Cathy Anne Pinto, Stephen Marcella, David A August, Bart Holland, John B Kostis, Kitaw Demissie

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Given their frequency of occurrence in the United States, cancer and heart disease often coexist. For patients requiring open-heart surgery, this raises concern that the use of cardiopulmonary bypass (CPB) may cause a transient immunosuppression with the potential to promote the spread and growth of coexisting cancer cells. This study examined the association of cardiopulmonary bypass with cancer progression in a large population-based setting using linked data from several state-wide registries.

Methods

A retrospective cohort study of cancer risk, stage, and mortality in 43,347 patients who underwent coronary artery bypass graft (CABG) surgery with and without CPB in New Jersey between 1998–2004 was conducted. A competing risk analogue of the Cox proportional hazards model with propensity score adjustment and regression on the cause-specific hazard was used to compute relative risk ratios (95% confidence intervals [CIs]) for patients undergoing CABG surgery with and without CPB.

Results

An increased risk for overall cancer incidence (17%) and cancer-specific mortality (16% overall, 12% case fatality) was observed; yet these results did not reach statistical significance. Of 11 tumor-specific analyses, an increased risk of skin melanoma (1.66 [95% CI, 1.08-2.55: p=0.02]) and lung cancer (1.36 [95% CI, 1.02-1.81: p=0.03]) was observed for patients with pump versus off-pump open-heart surgery. No association was found with cancer stage.

Conclusions

These results suggest that there may be a relationship between CPB and cancer progression. However, if real, the effect is likely modest at most. Further research may still be warranted with particular focus on skin melanoma and lung cancer which had the strongest association with CPB.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sablotzki A, Welters I, Lehmann N, Menges T, Gorlach G, et al: Plasma levels of immunoinhibitory cytokine interleukin-10 and transforming growth factor-β in patients undergoing coronary artery bypass grafting. Eur J Cardio Thorac Surg. 1997, 11 (4): 763-768. 10.1016/S1010-7940(97)01154-8.CrossRef Sablotzki A, Welters I, Lehmann N, Menges T, Gorlach G, et al: Plasma levels of immunoinhibitory cytokine interleukin-10 and transforming growth factor-β in patients undergoing coronary artery bypass grafting. Eur J Cardio Thorac Surg. 1997, 11 (4): 763-768. 10.1016/S1010-7940(97)01154-8.CrossRef
2.
go back to reference Markewitz A, Lante W, Franke A, Marohl K, Kuhlmann WD, Weinhold C: Alterations of cell mediated immunity following cardiac operations: clinical implications and open questions. Shock. 2001, 16 (Suppl 1): 10-15.CrossRefPubMed Markewitz A, Lante W, Franke A, Marohl K, Kuhlmann WD, Weinhold C: Alterations of cell mediated immunity following cardiac operations: clinical implications and open questions. Shock. 2001, 16 (Suppl 1): 10-15.CrossRefPubMed
3.
go back to reference Viera RD, Pereira AC, Lima EG, Garzillo CL, Rezende PC, et al: Cancer-related deaths among different treatment options in chronic coronary artery disease: results of a 6-year follow-up of the MASS II study. Coronary Artery Diesase. 2012, 23: 79-84. 10.1097/MCA.0b013e32834f112a.CrossRef Viera RD, Pereira AC, Lima EG, Garzillo CL, Rezende PC, et al: Cancer-related deaths among different treatment options in chronic coronary artery disease: results of a 6-year follow-up of the MASS II study. Coronary Artery Diesase. 2012, 23: 79-84. 10.1097/MCA.0b013e32834f112a.CrossRef
4.
go back to reference Mistiaen W, Van Cauwelaert P, Muylaert P, Wuyts F, Harrisson F, Bortier H: Effect of prior malignancy on survival after cardiac surgery. Ann Thorac Surg. 2004, 77: 1593-1597. 10.1016/j.athoracsur.2003.08.049.CrossRefPubMed Mistiaen W, Van Cauwelaert P, Muylaert P, Wuyts F, Harrisson F, Bortier H: Effect of prior malignancy on survival after cardiac surgery. Ann Thorac Surg. 2004, 77: 1593-1597. 10.1016/j.athoracsur.2003.08.049.CrossRefPubMed
5.
go back to reference Carrascal Y, Gualis J, Arevalo A, Fulquet E, Florez S, Rey J: Cardiac surgery with extracorporeal circulation in cancer patients: influence on surgical morbidity and mortality on survival. Rev Esp Cardiol. 2008, 61 (4): 369-375. 10.1157/13117728.CrossRefPubMed Carrascal Y, Gualis J, Arevalo A, Fulquet E, Florez S, Rey J: Cardiac surgery with extracorporeal circulation in cancer patients: influence on surgical morbidity and mortality on survival. Rev Esp Cardiol. 2008, 61 (4): 369-375. 10.1157/13117728.CrossRefPubMed
6.
go back to reference Platell C: Influence of cardiopulmonary bypass surgery on cancer-specific survival rate of patients with colorectal cancer. Dis Colon Rectum. 1998, 41: 1371-1375. 10.1007/BF02237052.CrossRefPubMed Platell C: Influence of cardiopulmonary bypass surgery on cancer-specific survival rate of patients with colorectal cancer. Dis Colon Rectum. 1998, 41: 1371-1375. 10.1007/BF02237052.CrossRefPubMed
7.
go back to reference Suzuki S, Usui A, Yoshida K, Matsuura A, Ichihara T: Effect of cardiopulmonary bypass on cancer prognosis. Asian Cardiovasc Thorac Ann. 2010, 18: 536-540. 10.1177/0218492310388453.CrossRefPubMed Suzuki S, Usui A, Yoshida K, Matsuura A, Ichihara T: Effect of cardiopulmonary bypass on cancer prognosis. Asian Cardiovasc Thorac Ann. 2010, 18: 536-540. 10.1177/0218492310388453.CrossRefPubMed
11.
go back to reference Redelings MD, Wise M, Sorvillo FC: Using Multiple Cause-of-Death Data to Investigate Associations and Causality Between Conditions Listed on the Death Certificate. Am J Epidemiol. 2007, 166: 104-108. 10.1093/aje/kwm037.CrossRefPubMed Redelings MD, Wise M, Sorvillo FC: Using Multiple Cause-of-Death Data to Investigate Associations and Causality Between Conditions Listed on the Death Certificate. Am J Epidemiol. 2007, 166: 104-108. 10.1093/aje/kwm037.CrossRefPubMed
12.
go back to reference Rosenbaum PR, Rubin DB: The central role of the propensity, score in observational studies for causal effects. Biometrika. 1983, 79: 516-524. Rosenbaum PR, Rubin DB: The central role of the propensity, score in observational studies for causal effects. Biometrika. 1983, 79: 516-524.
13.
go back to reference Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, et al: Variable selection for propensity score models. Am J Epidemiol. 2006, 163: 1149-1156. 10.1093/aje/kwj149.CrossRefPubMedPubMedCentral Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, et al: Variable selection for propensity score models. Am J Epidemiol. 2006, 163: 1149-1156. 10.1093/aje/kwj149.CrossRefPubMedPubMedCentral
14.
go back to reference Westreich D, Cole SR, Funk MJ, Brookhart A, Stuermer T: The role of the c-statistic in the variable select for propensity score models. Pharmacoepidemiol Drug Saf. 2011, 20: 317-320. 10.1002/pds.2074.CrossRefPubMed Westreich D, Cole SR, Funk MJ, Brookhart A, Stuermer T: The role of the c-statistic in the variable select for propensity score models. Pharmacoepidemiol Drug Saf. 2011, 20: 317-320. 10.1002/pds.2074.CrossRefPubMed
15.
go back to reference Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: competing risks and multistate models. Stat Med. 2007, 26: 2389-2430. 10.1002/sim.2712.CrossRefPubMed Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: competing risks and multistate models. Stat Med. 2007, 26: 2389-2430. 10.1002/sim.2712.CrossRefPubMed
16.
go back to reference Lin DY, Wei LJ: The robust inference for the proportional hazards model. Journal of the American Statistical Assocation. 1989, 84: 1074-1078. 10.1080/01621459.1989.10478874.CrossRef Lin DY, Wei LJ: The robust inference for the proportional hazards model. Journal of the American Statistical Assocation. 1989, 84: 1074-1078. 10.1080/01621459.1989.10478874.CrossRef
17.
go back to reference Harrell F, Lee K: Verifying assumptions of the proportional hazards model. Proceedings of the eleventh annual SAS users’group international. 1986, 823-828. Harrell F, Lee K: Verifying assumptions of the proportional hazards model. Proceedings of the eleventh annual SAS users’group international. 1986, 823-828.
19.
go back to reference Crespo-Leiro , Villa-Arranz A, Manito-Lorie N, Paniagua-Martin MJ, Rabago G, et al: Lung Cancer After Heart Transplantation. Results from a Large Multicenter Registry. Am J Transplant. 2011, 11: 1035-1040. 10.1111/j.1600-6143.2011.03515.x.CrossRefPubMed Crespo-Leiro , Villa-Arranz A, Manito-Lorie N, Paniagua-Martin MJ, Rabago G, et al: Lung Cancer After Heart Transplantation. Results from a Large Multicenter Registry. Am J Transplant. 2011, 11: 1035-1040. 10.1111/j.1600-6143.2011.03515.x.CrossRefPubMed
20.
go back to reference Kirk GD, Merlo C, Driscoll PO, Mehta SH, Galai N, et al: HIV Infection is Associated with an Increased Risk for Lung Cancer, Independent of Smoking. Clin Infect Dis. 2007, 45 (1): 103-110. 10.1086/518606.CrossRefPubMedPubMedCentral Kirk GD, Merlo C, Driscoll PO, Mehta SH, Galai N, et al: HIV Infection is Associated with an Increased Risk for Lung Cancer, Independent of Smoking. Clin Infect Dis. 2007, 45 (1): 103-110. 10.1086/518606.CrossRefPubMedPubMedCentral
Metadata
Title
Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study
Authors
Cathy Anne Pinto
Stephen Marcella
David A August
Bart Holland
John B Kostis
Kitaw Demissie
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-519

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine